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Discovering new potential
inhibitors to SARS‑CoV‑2 RNA
dependent RNA polymerase (RdRp)
using high throughput virtual
screening and molecular dynamics
simulations
Dylan Brunt , Phillip M. Lakernick  & Chun Wu *
RNA dependent RNA polymerase (RdRp), is an essential in the RNA replication within the life
cycle of the severely acute respiratory coronavirus-2 (SARS-CoV-2), causing the deadly respiratory
induced sickness COVID-19. Remdesivir is a prodrug that has seen some success in inhibiting this
enzyme, however there is still the pressing need for effective alternatives. In this study, we present
the discovery of four non-nucleoside small molecules that bind favorably to SARS-CoV-2 RdRp over
the active form of the popular drug remdesivir (RTP) and adenosine triphosphate (ATP) by utilizing
high-throughput virtual screening (HTVS) against the vast ZINC compound database coupled with
extensive molecular dynamics (MD) simulations. After post-trajectory analysis, we found that the
simulations of complexes containing both ATP and RTP remained stable for the duration of their
trajectories. Additionally, it was revealed that the phosphate tail of RTP was stabilized by both
the positive amino acid pocket and magnesium ions near the entry channel of RdRp which includes
residues K551, R553, R555 and K621. It was also found that residues D623, D760, and N691 further
stabilized the ribose portion of RTP with U10 on the template RNA strand forming hydrogen pairs with
the adenosine motif. Using these models of RdRp, we employed them to screen the ZINC database
of ~ 17 million molecules. Using docking and drug properties scoring, we narrowed down our selection
to fourteen candidates. These were subjected to 200 ns simulations each underwent free energy
calculations. We identified four hit compounds from the ZINC database that have similar binding poses
to RTP while possessing lower overall binding free energies, with ZINC097971592 having a binding
free energy two times lower than RTP.
The highly contagious coronavirus induced illness COVID-19 is now a global threat to human well-being, with
the current case numbers rising near 220 million and over 4.5 million deaths as of September 2021. With the
increase in rollouts of vaccinations around the world, there are now some signs of relief to even the most affected
regions. However, there is still the potential for new vaccine resistant strains of the coronavirus are evolving often
as seen in the recent deadly outbreak of the new B.1.617.2 “Delta” variant in Nepal1. Additionally, there is the
possibility for some vaccinated individuals to not develop an adequate immune response to create neutralizing
antibodies. Therefore, there is still an urgent need for effective drug therapy in order to slow down the progression
of sickness in affected patients. The SARS-CoV-2 virus is a positive-strand RNA virus whose genomic structure
expresses high similarity with previous severe acute respiratory syndrome coronavirus (SARS-CoV). Like other
RNA viruses, the replication of SARS-CoV-2 requires RNA-dependent RNA polymerase (nsp 12), a key enzyme
which regulates the viral genome replication and transcription within the viral life cycle. It is thus a key validated
target for the development of COVID-19 disease small molecule therapeutics.
Currently, Gilead’s Remdesivir (RDV) otherwise known as VekluryⓇ has been approved by the FDA as an
antiviral prodrug which targets the nucleotide addition process in RdRp. This prodrug is bio transformed in the
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Method

Protein target

Ligand library

Extension reactions

None

6 FDA approved antiviral agents

# Output
6

Chien et al.4

Extension reactions, exonuclease reactions

None

Sofosbuvir

1

Jockusch et al.2

Extension reactions

None

Oligonucleotides purchased from DNA Technologies

3

Ju et al.5

Therapeutics

6NUR

10 Antiviral drugs

2

Aftab et al.6

Virtual screening

6M71

FDA Approved database of 7922 molecules

7

Ahmad et al.7

Virtual screening

6NUR, 6NUS

11 Favipiravir analogues

1

Aktas et al.8

Docking, ADMET analysis, bioactivity prediction

6M17

113 Quinoline-drugs

5

Alexpandi et al.9

Docking

6NUR

5 Pharmaceutical drugs

5

Al-Masoudi et al.10

Systematic screening, bioassays

6NUR

4947 Drugs from DrugBank, ChEMBL, Binding Database

Docking

5B6O

16 Antiviral drugs

4

Calligari et al.12

Docking

6M71

7 Falvonoid drugs

2

da Silva et al.14

Docking

6M71

171 Essential oil components

3

da Silva et al.13

Sequence analysis, docking, modeling

6NUR

8 Pharmaceutical drugs

4

Elfiky15

Virtual screening

6M71, 7BTF

65 FDA approved small molecule antiviral drugs

5

Indu et al.17

Comprehensive analysis

7BV2

22 FDA approved drugs

2

Kandeel et al.18

Docking

Crystal Structure

Carotane sesquiterpenes

1

Mohamed et al.19

Docking

6M71, 7BV2

44 Drug candidates

5

Parvez et al.20

Virtual screening

6M71, 6NUR

FDA approved drugs

1

Pokhrel et al.21

Docking, free energy calculations

6NUR

8 FDA approved drugs

8

Ruan et al.22

Modeling

6YYT

2924 Compounds from the approved drug database

1

Tchesnokov et al.23

Modeling, Docking

Homology Model

FDA Approved drug database

Virtual screening

384 PDB Structures

7894 Drug data compounds

Docking, MD simulation (100 ns)

6NUR, 6M71, 7BTF

76 Perscription drugs

4

MD simulation (30 ns)

6NUR

3277 Approved drugs

3

Docking, MD simulation (3.99 ns)

6M71

13 Alkaloids from Cryptolepis sanguinolenta

MD simulation (100 ns), docking

7BTF, 6M17

29 Bioactive compounds from South African medicinal
plants

4

Dwarka et al.29

Docking, MD simulation (150 ns)

7BV2

MAW-22 (FBDD of the top 5 fragments)

1

El Hassab et al.30

Modeling, docking, MD simulation (51 ns)

6NUR, 7BTF, 6M71

30 Drugs against the SARS-CoV-2 RdRp

15

MD simulation (260 ns), modeling, docking

2XI3

7 Pharmaceutical drugs

4

Elfiky et al.15

MD simulation (50 ns)

6M71

8 Pharmaceutical drugs

8

Elkarhat et al.41

MD simulation (20 ns), docking

6NUR

A select number of pharmaceutical drugs from the FDA

MD simulation (5.5 ns), docking

7BV2

97 Natural amide-like compounds

3

Gutierrez-Villagomez et al.32

Docking, MD simulation (40 ns)

7BV2

12 Species of Clerodendrum

1

Kar et al.33

Docking, MD simulation (100 ns)

6M71

617 Source species from Northern South Africa

5

Khan et al.34

MD simulation (100 ns)

6M71

FDA approved and investigational drug

2

Mutlu et al.35

MD simulation (50 ns)

6M71, 7BV2

Various libraries of FDA approved drugs, natural products,
antiviral compounds, and drug repurposing compounds

1

Narayanan et al.36

Docking, MD simulation (10 μs)

6M71, 6NUR

8800 Drug structures obtained from DrugBank

Docking, MD simluation (50 ns)

6M71

Docking, MD simulation (50 ns)

6NUR

102

135
10

13

18

Author

Ao et al.11

Wu et al.24
Zhao et al.25
Ahmed et al.26
Barage et al.27
Borquaye et al.28

Elfiky16

Gul et al.31

10

Ribaudo et al.37

22 Major bioactive molecules from 10 medicinal plants

7

Sharma et al.38

12 FDA approved drugs 6

6

Singh et al.39

Table 1.  Survey of the current studies on the discovery and/or repurposing of approved drugs for the
inhibition of SARs-COV-2 RdRp.

body into the active-form remdesivir-triphosphate (RTP), a nucleoside mimic to adenosine triphosphate (ATP),
which then undergoes nucleotide addition onto the growing RNA chain2. It is theorized that RDV inhibits RdRp
by chain termination during the RNA translocation s tep3. Its action on treating SARS-CoV-2 infection has seen
some success in reducing the time needed for recovery in very sick patients that require h
 ospitalization4. However, this drug’s efficacy is also controversial, as its administration was recently halted due to the lack of significant
improvement expected in COVID-19 infected patients. Therefore, because RDV is the only FDA approved drug
for treating COVID-19 patients, there is interest in the discovery of alternative treatments. Additionally, there
is interest in developing non-nucleoside mimetics with high RdRp affinity for this purpose, as these are thought
to circumvent the polymerization reaction.
There is a remarkable effort underway from researchers around the globe to help shed more light on potential alternatives for the inhibition of RdRp. There have been several studies (Table 1)3,5–42 that have reported
the discovery of potential small molecule inhibitors of RdRp, mostly deriving from the in-silico approach
coupled with virtual drug screening of numerous compound libraries. As of this study, few in-silico studies
have considered the approach of using the massive ZINC library of approximately 17 million compounds
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Figure 1.  Virtual screening workflow designed to conduct this study.

using high-throughput virtual screening workflow (Fig. 1) paired with long, multi-system molecular dynamics (MD) s imulations43. A previous study reported the discovery of two potential isoformic RdRp inhibitors:
ZINC09128258 and ZINC09883305, however these were observed to have lower docked binding affinity than
the compared standards21.
In our present study, we have utilized long MD simulations (1.0 µs) each of SARS-CoV-2 RdRp in complex
with free form active RTP and ATP and template-primer RNA starting from the recently solved crystal complex (PDBID: 7BV2)44. Using the most abundant conformations of RTP complex from 1.0 µs simulations, we
performed pharmacophore-based screening of the ZINC 15 library against the binding site of RdRp, leading to
fourteen compounds with top docking s cores43. From these top fourteen compounds, we performed classical
MD simulations (200 ns each) to observe the stability for each complex system. Lastly, we performed Molecular
Mechanism-General Born Surface Area (MM-GBSA) energy predictions to observe their relative binding affinities to RdRp after s imulation39,45–47. Four ZINC compounds showed stable binding to the RdRp-RNA complex.
Additionally, these four systems showed improved MM-GBSA energies both the RTP and ATP complex systems
as well as in reference to their initial docked complexes. This discovery helps introduce crucial knowledge of
small molecule binding to RdRp in addition to the effort in discovering and development of anti-SARS-CoV-2
RdRp agents using in-silico methods.

Experimental section

Structure building and ligand preparation. The recent electron microscopy solved crystal structure
of SARS-COV-2 nsp12-nsp7-nsp8 RdRp in complex with template-primer RNA and covalently bound RDV
named PDB ID 7BV2 was retrieved from the RCSB protein database44,48. This structure was then prepared
with the default charge state being optimized at pH 7 using Maestro’s built-in Protein Preparation Wizard49–51.
The complex was then preprocessed, optimized, and minimized using the Protein Preparation Wizard within
Maestro software49. A receptor docking grid was generated around the covalently bound RDV with a X: 7.07,
Y: − 3.87 and Z: 1.27 spatial coordinates and a grid box size allowing for ligands with length ≤ 20 Å. Free form
RTP was then generated by breaking phosphodiester bonds between U20 of primer strand and remdesivir. The
phosphate tail was then added onto the 5′ carbon of remdesivir to render the triphosphate form bound within
the i binding site. The ligand RTP was then redocked using the receptor grid file generated prior. The resulting
docking grid was also applied for the docking of ATP towards RdRp. Before any docking procedures, the ligands
were first prepared for docking by generating the ionization/tautomeric states at pH 7 ± 2 using Maestro’s Epik
tool52,53. Each ligand was docked utilizing the Glide module within Maestro software and the GlideXP scoring
function was employed50,51,54.
MD system setup. The OPLS2005 force field was used to model the protein and the ligands55–57. When
creating a MD simulation system for RDV-TP, ATP and the 14 ZINC compounds, its XP docked complex with
the two crystal M
 g2+ ions was placed into an orthorhombic water box with a buffer distance of 10 Å using the
SPC water m
 odel58 and a salt concentration of 0.15 M NaCl was added to the system55,56.
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Relaxation and production runs.

The MD simulations for each system were performed using the Desmond simulation package59 and the default simulation protocols were followed just like our early work60–62. Here
a brief description is given. Each system was relaxed using the default relaxation protocol for non-membrane
proteins63. There are eight stages which constitute the protocol: (1) minimization of the system with a restraint of
solute heavy atoms. (2) Minimization without any restraints. (3) Simulation with heating from 0 to 300 K, H2O
barrier and gradual restraining. (4) Simulation under the NPT ensemble which is constant number of particles,
pressure of 1 bar and constant temperature of 300 K with an H2O barrier and heavy atoms being restrained.
(5) Simulation under the NPT ensemble with equilibration solvent. (6) Simulation under the NPT ensemble
with protein heavy atoms annealing from 10.0 to 2.0 kcal/mol. (7) Simulation under the NPT ensemble with
Cα atoms restrained at 2.0 kcal/mol; and (8) simulation of 1.5 ns under the NPT ensemble with no restraints.
After this relaxation procedure, six 1000 ns production runs for RTP, ATP and four top zinc ligand systems,
and ten 200 ns production runs were conducted under the NPT ensemble using the default protocol, leading
to a total of 8000 ns. M-SHAKE64 was used to constrain bonds with hydrogen atoms, which allowed for 2.0 fs
time steps during the simulation. Long-range electrostatic interactions were treated under periodic boundary
conditions by the k-space Gaussian split Ewald m
 ethod65. The charge grid spacing was ~ 1 Å and the direct sum
tolerance was 1 0–9. Van der Waals interactions were based on a uniform density approximation. A distance of
9 Å was set as the cutoff for short range non-bonded interactions. Non-bonded forces were calculated by an
r-REPA integrator66; the short range forces updated every 2 fs and the long range every 6 fs. The trajectories were
saved every 50 ps for analysis. Pressure of 1 bar was controlled using the Martyna–Tobias–Klein chain coupling
scheme67 (coupling constant = 2 ps), and temperature of 300 K by the Nosé–Hoover67 chain coupling scheme
(coupling constant = 1 ps).

Conformational clustering of RdRp complexes. The Desmond trajectory clustering tool was used to
group the complex structures from the last 100 ns of simulation for the ATP and RTP systems58. The merging
distance cutoff was set to be 2.5 Å. The centroid representative (i.e. the structure having the largest number of
neighbors in the structural family) was used to display the structural family. The most abundant conformations
are identified as the cluster with the most occupancy. This was performed for the complexes containing ATP and
RTP. Clustering was then performed on the top fourteen ZINC compounds selected from HTVS after 200 ns
simulation.
Pharmacophore screening and hit prioritization. The pharmacophore screening was performed
using the active Remdesivir against ZINC product molecules using LigandScout 4.368. In our model, we determined the seven pharmacophore features to include the two negative ionizable groups, one aromatic ring, and
four hydrogen bonds acceptors with their corresponding positions. Before further experiments, we determined
the ionizable/tautomeric states of each compound under pH 7 ± 2 using Maestro’s Epik tool52,53. The lowest ionization/tautomeric states were selected, and their bond geometries were minimized to the lowest energetic state.
We then employed our prepared RdRp complex to generate a receptor grid file around the RTP binding site,
or i site, and the ionization, tautomeric and bond states of ATP were generated at pH ± 2 using Maestro’s Epik
tool52,53. This receptor grid file was additionally used for our docking of the ZINC database compounds using the
Glide XP docking scoring function within Maestro software49,68. High-Throughput Virtual Screening (HTVS)
was also performed using the Glide module on the most abundant cluster representative of the RTP system after
simulation utilizing the ZINC15 compound database43,50,51. This process consists of screening at three levels
with gradually increasing the computational cost. The first level is based on ligand ADME/Toxicity prediction
using QikProp of Schrodinger and docking using G
 lide69. The second is performed using MD simulations of
the docked complexes with explicit solvents (water)63. Lastly, the third is determined by the binding energy
calculations. After HTVS, we narrowed down the library of compounds to the top fourteen based on their
superior Glide scores and #star value50,51. We then subjected these fourteen to 200 ns simulations and performed
MM-GBSA calculations to determine their relative binding affinities after the s imulation39,45. From the fourteen
compounds, four compounds were selected based on their favorable binding energies.
Confirmation of stability of hits and MM‑GBSA calculation. The Desmond SID module was
employed to analyze the interaction between proteins and ligands as well as to determine their stability in each
MD simulation63. This includes the Root-Mean Square Deviation (RMSD) of the protein–ligand complexes and
Root-Mean Square Deviation (RMSF) of both the protein and ligands. Additionally, secondary structure elements (SSE) were explored. Lastly, the protein–ligand contacts containing H-bond, ionic, hydrophobic interactions were explored.
In order to check the convergence of the simulations, we investigated the root mean square deviation (RMSD)
values of protein Cɑ, RNA O5′ atoms, and ligand main atoms for each trajectory using the SID tool within Maestro software63. The root mean square fluctuation (RMSF) of each individual amino acid, RNA and ligand atom
were also calculated to characterize the local movement of individual structural components of each complex.
The Molecular Mechanism-General Born Surface Area (MM-GBSA) binding energies were calculated on the
frames for the whole duration of both systems as well as for each ZINC s ystem45. The OPLS3 force field, VSGB 2.0
solvation model and the default Prime procedure was used for the MM-GBSA calculations46,47,55–57,70. The default
procedure consists of three steps: Receptor alone (minimization), Ligand alone (minimization), Receptor-ligand
complex (minimization). The total binding free energy equation is: ΔGBind = Ecomplex (minimized) − (Eligand (minimized)
+ Ereceptor(minimized)). To gain a more detailed understanding of binding nature, the original interaction terms
(Coulombic + H-bond + GB solvation + van der Waals + π–π packing + self-contact + lipophilic) were merged
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into three components: E electrostatics, EvdW, and E lipophilic, where E electrostatics = ( H bond + E coulomb + E GBsolvation),
EvdW = (EvdW + Eπ-π + Eself-contact) and Elipophilic.

Normal mode analysis by PCA. The trajectory of ATP, RTP and the four top zinc ligands was used in the
Normal Mode Wizard in VMD71 to generate the top 5 normal modes by a principal component analysis (PCA).

Results and discussion

The binding of remdesivir triphosphate and ATP to RdRp. Adenosine triphosphate was docked

against the crystal structure of SARS-CoV-2 RdRp (PDBID: 7BV2) at the i-binding site which formed hydrogen
pairing with the template strand of 14 nucleotide bases and the primer strand of 11 nucleotide bases44. The conformational pose of the docked RTP compared to the covalently bound RDV in the crystal structure was nearly
identical (Fig. S2). We then generated a docking grid from the docking pose of RTP to dock ATP into the same
catalytic site of RdRp. The conformational pose of ATP compared to the covalently bound crystal RDV was
nearly identical. It was also seen that the triphosphate tail of RTP was positioned near one of the M
 g+ ions. These
conformations were then used to perform long (1.0 µs) simulations for each complex to further elucidate more
about the relaxed conformations of each and to obtain a stable conformation for our high-throughput virtual
screening portion of the study.
The trajectory convergence of the simulation for both systems was confirmed through analyzing the RMSD
during the 1000 ns (1.0 µs) simulations shown in Fig. 2A,B. The trajectory RMSD is of the protein receptor backbone Cɑ atoms and the ligand main atoms for both the ATP and RTP complexes. It is clearly seen in Fig. 2A that
the RTP system reached stability very early in the simulation (~ 50 ns) while the ATP system in Fig. 2B reached
stability around 550 ns. Importantly, both protein complexes maintained average RMSD values of approximately
2.0 Å. This is indicative that the differences between ATP and RTP binding had no significant change in the
overall RdRp conformation through the 1.0 µs simulation.
The ligand RMSD average values for the ATP system are within 1 Å of the protein RMSD values and reached
stability at approximately 550 ns. The ligand RMSD for the RTP system also matched the average distance as in
the protein with a convergence very early in the simulation; approximately 50 ns. It is clearly seen that the complex containing ATP possessed higher RMSD values compared to the RTP complex indicating that the binding
of RTP was more stable during the simulation.
We additionally wanted to confirm the stability of the template-primer RNA in the complex through simulation. The RMSD of the RNA main atoms is shown in Fig. S3, both ATP and RTP systems show clear stability
and early convergence at around 50 ns with values both approximately 2.0 Å which is also consistent with the
protein Cɑ RMSD. Likewise seen in the ligand main atoms RMSD plot, the complex containing RTP showed
slightly lower average values compared to the ATP system indicating more stable binding occurred during the
simulation. To observe the fluctuation of each individual amino acid in the protein structure, we recorded the
RMSF of the RdRp complexes during the simulation.
Ligand main atoms RMSF (Fig. S5) was also recorded to observe the fluctuation of the individual atoms of
each ligand in order to better understand the regions of stability of ATP and RTP. Clearly, RTP in complex saw
less fluctuation per atom over the simulation as compared to ATP. Short peaks at atoms 1–4 indicate the slight
instability seen in the gamma phosphate on the phosphate tail which is not abnormal. Interestingly, small peaks
in atoms 16 and 30 indicate a slight increase in fluctuation seen at the 3′ and 4′ hydroxyl groups on the ribose
ring of RTP. This specificity at only these two polar functional groups is also seen in atoms 29 and 30 of the ATP
system and likely indicates positioning for nucleophilic attack during nucleotide addition.

Clustering analysis. We then performed cluster analysis of both MD systems after the simulation to generate the most abundant conformational pose during the 1000 ns duration. In the 2D residue interaction seen with
the most abundant conformational poses of each simulation (Fig. 3A–F), it was observed that the adenine motif
of both ATP and RTP maintained H-Bond pairing with U10 on the template strand and partial pi-pi stacking of
A11 on the primer strand. The RTP system was more able to sustain salt bridge interactions with positive residues R555, R553, R624, K621. The RTP system also saw interaction with S759 on the nitrile group while Y619
was seen to form H-Bonds with negative oxygen on the gamma phosphate of ATP. In addition, the RTP system
also saw stabilization of the 3′ hydroxyl group on the ribose ring by H-Bonds with residues N691 and T680.
During the 1.0 µs simulation of both the ATP and RTP systems, several amino acid contacts were observed
to be maintained throughout with high occupancy (Table S7). For both the ATP and RTP systems, there was
significant occupancy in the H-Bond interactions between the triphosphate tails and a positive region of amino
acids such as K551, K621, K798, R553 and R555 of ≥ 30% of the simulation time. For the RTP complex, residues
K621, R553 and R555 formed H-bonds with negatively charged oxygen on alpha, beta and gamma phosphate
with all possessing an occupancy of above 90%, indicating that these contacts could be crucial for the stability and positioning of RTP in the catalytic site of RdRp. These interactions were seen in previous study where
both ATP and RTP were docked to R
 dRp72. Both systems also maintained the maximum occupancy interaction
with Mg+ ions with the triphosphate tails, suggesting that at least one ion is responsible for the stabilization and
positioning of incoming nucleotides. There was modest occupancy of hydrogen bond formation with hydroxyl
groups located on the ribose ring portions with residues D623, D760, and N691, indicating secondary stabilizing
roles for these amino acids potentially related to the initiation of nucleotide addition. Negative residue D623 saw
an average occupancy of 56% bonding with both hydroxyl groups of the ribose ring portion of RTP. In the ATP
complex, D760 saw 34% occupancy with the 3′ hydroxyl group located on the ribose ring which is involved in
nucleotide addition.
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Figure 2.  The RMSD values for the receptor Cα and ligand main atoms for the RTP, ATP and four ZINC
systems. Protein Cα is shown in blue and ligand main atoms is shown in red. Figure (A) is the system containing
RTP, (B) is the system containing ATP, (C) is the system containing ZINC097971592, (D) is the system
containing ZINC002146610, (E) is the system containing ZINC069492350 and (F) is the system containing
ZINC408592119.

In Table S6 are the histogram of protein–ligand contacts occupancy during the simulations for ATP and
RTP complexes. These show the smaller contacts seen with occurrence of ≤ 30% of the simulation as well as
contacts that occurred at over 100% which indicates multiple ligand atoms contacting same amino acid. In the
ATP complex, the ligand contacted several more protein residues with brief occupancy compared to the RTP
complex which is likely due to lower relative ligand bound stability seen in the former. Also, more water bridge
interactions occurred with the ATP complex indicating weaker overall affinity compared to the RTP complex.
Furthermore, RTP saw higher occupancy of H-bonds compared to others confirming the relative favorability
of bonding to RdRp.
Previous studies have also reported similar findings on the critical amino acids involved in RDV binding.
Koulgi et al. described an ensemble approach of the free form binding of prodrug RDV in complex with SARSCoV-2 RdRp contacted amino acids Y451, T540, M542, R548, K551, R553, R555, A558, D618, S674, D761 and
E81173. Amino acid R555 was observed to form H-bonds with the alpha phosphate group in RDV in all five
ensemble representatives73. Other studies have aimed to observe the active triphosphate form interaction upon
RdRp binding. Zhang et al. found that the nitrile group was positioned in a pocket including K545, Y546 and
A547 with the phosphate tail interacting with K551, R553 and R555. Additionally, positive amino acids near the
palm subdomain were found to be crucial for RTP a ctivity74.
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Figure 3.  Ligand–receptor interaction diagrams and representations of the most abundant conformational
pose from MD simulation. (A,D) The 3D surface representation of SARS-CoV-2 RdRp colored in yellow. (B,E)
Zoomed and rotated perspective of the template-primer RNA in complex with ATP and RTP, respectively.
(C,F) The detailed receptor-RNA-ligand contacts of the most abundant conformational pose of ATP and RTP,
respectively. Template and primer strands represented in blue and red licorice, respectively. Ligands are colored
in green and magnesium ions are represented as pink balls.

Normal mode analysis. To probe the dynamics of the two systems (ATP vs RTP), the trajectory was ana-

lyzed by a PCA analysis to generate top five low frequency normal modes of ATP (Fig. S6a) and RTP (Fig. S6b).
By visual inspection, although the two systems undergoes a similar opening and closing motion in their normal
modes, subtle differences in magnitude between the two systems was also identified in some modes. For example, the APT system appears to have larger inter-domain movement than the RTP system among the three key
RNA binding domains: Thumb domain, Palm domain and Finger domain. To show this, the mode 5 of the ATP
system and the mode 1 of the RTP are shown in Fig. 4 and the movie files are provided in the supporting info.
Because the ATP and RTP in these complex have already in a closed active site conformation, the translocation
is the next critical step for growing the primer strand after incorporating AMP/RMP into the primer stand,
this larger opening-closing mode of the ATP system than the RTP might forecast some critical difference in
the translation step between the two systems. Interestingly, RTP has been found to halt RNA extension at the
i + 3 site after RMP is incorporated into the RNA primer strand, through stalling the translocation of the primer
strand75. In contrast, ATP does not have this translocation problem. In Fig. S6a, it can be observed that each
mode undergoes a different opening and closing motion.
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Figure 4.  The top view (top) and the side view (bottom) of a selected normal mode from the ATP (model 5)
and RTP system (model 1). RNA (yellow) and Thumb domain (Red), Palm domain (Green), and Finger domain
(Blue) of RdRp is shown ribbon.

High‑throughput virtual screening finds 14 compounds. Once we validated that our simulations
with ATP and RTP bound to RdRp met convergence during the simulation, we then used these complexes to
perform our initial screening. Firstly, pharmacophoric screening of the ZINC database was performed by selecting seven pharmacophoric features, i.e. two negative ionizable, one aromatic ring, and four H-bond acceptors of
RTP. Shown in Table 2 is the results from HTVS docking against RdRp to retrieve the top fourteen hits with the
highest GlideXP scores and lowest #stars as the determining factors. The GlideXP scores measured in kcal/mol
are tabulated based on decreasing favorability. A more negative GlideXP score typically indicates a good initial
binding affinity to RdRp. The initial conformational pose of each ligand in complex with RdRp and RNA as well
as their detailed 2D ligand contacts is shown in Table S2. These fourteen compounds were then subjected to classical 200 ns MD simulations and further MM-GBSA energy calculations for each.
The MM-GBSA energies and average protein–ligand RMSD of all fourteen MD simulations are summarized
in Table S3. Within Fig. 5A,B show the ligand RMSD and RMSF values of all fourteen ZINC candidates with ATP
and RTP systems calculated over the last 100 ns of simulation. The free energy of binding gives a more accurate
insight into both the simulation efficacy and flexible binding affinity of ligands to their target as opposed to rigid
ligand docking. The summary of the 200 ns simulation runs and MM-GBSA energy calculation in Table S3 shows
that several compounds possessed more favorable free energy of binding compared to the ATP and RTP systems.
From this subset of ligands, we selected the top four with the most favorable MM-GBSA calculated energies
for further convergence analysis to ensure that the conformational stability was reached and maintained. The
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Molecule

Docking score (kcal/mol)

# Stars

ZINC000014651456

− 13.5

0

ZINC000257306096

− 12.9

0

ZINC000238950253

− 12.8

0

ZINC000299798705

− 12.7

0

ZINC000067790716

− 12.4

0

ZINC000089920955

− 11.9

0

ZINC000097971592

− 11.8

1

ZINC000065742965

− 11.7

0

ZINC000016040970

− 11.6

0

ZINC000408592119

− 11.6

0

ZINC000237948681

− 11.5

0

ZINC000069492350

− 11.4

0

ZINC000002146610

− 11.2

0

ZINC000084651559

− 11.2

0

Table 2.  Summary of docking results and pharmacokinetic information of the top 14 ZINC candidates.
Docking score is empirically calculated in kcal/mol from rigid receptor GlideHTVS protocols which help
define compounds with good binding affinity. The scoring function is comprised of lipophilic, hydrogen
bonding, hydrophobic terms as well as a rotable bond penalty. The #stars is a parameter defined by QikProp
module and scores compounds based on their similarity to known medicines.

molecular structures of the four candidates are shown in Fig. 6. Furthermore, in Fig. 2C–F shows the RMSD
of protein Cα atoms and ligand main atoms projected over the duration for these selected compounds. The
protein portions reached convergence early in the simulation for each system containing ZINC097971592,
ZINC002146610, ZINC069492350 and ZINC408592119. It was observed that the RMSD values of the protein Cα of the four ZINC systems were lower than that of the RTP system. Also, the ligand RMSD values for
ZINC097971592 and ZINC408592119 were higher than that of the RTP complex.
We additionally wanted to observe the RMSF of the RNA main atoms during simulation to gain some more
insight into the individual fluctuation of each nucleotide in the RNA sequence. In Fig. 7A, this displays the
template-primer RNA RMSF obtained from the O5′ atoms on the RNA backbone for ATP and RTP systems and
the four ZINC systems with Fig. 7B indicating the nucleotide sequence indexing used during the recording. The
RMSF values were high at nucleotides G1-U3 on the 5′ end of the primer strand as well as high peaks around
A22–C25 towards the 3′ end of the template strand for all 6 systems. This indicates high fluctuation induced from
the exposure to solvent. In the middle of the plot is a slight peak around U12 on the template strand indicating
that this portion did not interact with either ligand. Nucleotides U13-A15 on the template strand show a sharp
decrease in fluctuation which is most likely due to the binding and hydrogen pairing of both ATP and RTP.
The average RMSD values over the last 50 ns of simulation for receptor and ligand is also summarized in
Table 3. The four ZINC systems maintained similar average receptor RMSD values were approximately 3.9 Å
which is near the value of the ATP system of 2.4 Å. This result suggests the RdRp complex system remained in
similar conformational state regardless of their structure dissimilarity against ATP. Table 3 is also a breakdown
of the individual MM-GBSA terms such as the Van der Waals (ΔGVDW), electrophilic (ΔGELE) and lipophilic
(ΔGHYD) energies of the top four selected ZINC compounds as well as ATP and RTP for comparison. The summation of these term equates to the relative free energy of binding (ΔGTotal) measured in kcal/mol. Clearly, the
four selected compounds from the ZINC database resulted in lower overall MM-GBSA values over the ATP
and RTP systems of − 35.9 ± 3.1 kcal/mol and − 21.3 ± 5.9 kcal/mol, respectively. The RdRp complex containing ZINC069492350 had the most negative MM-GBSA value of − 43.8 ± 4.1 kcal/mol, with ZINC002146610,
ZINC097971592 and ZINC408592119 having values of − 32.4 ± 5.1, − 37.4 ± 8.1 and − 31.4 ± 4.9 kcal/mol, respectively. A conserved trend was seen in the decomposition of each contributing energy term with the Van der
Waals ΔGVDW contributing the most towards the overall ΔGTotal especially for the case of the ZINC compounds.
This is likely attributed simply to the high contract between nucleotides and the ZINC compounds in molecular
mass, atom count and therefore a larger electron cloud to induce fluctuation to adjacent residues in the enzyme
pocket. The average RMSD was also provided to confirm the stability off each system compared to the standard.
The four ZINC systems maintained a similar average receptor RMSD value of approximately 3.3 Å compared
to 2.4 Å of the ATP system. This result suggests the RdRp complex system of each ZINC system remained in a
slightly more unstable conformational state against the ATP system.
The detailed 2D receptor-RNA-ligand contacts diagrams of the most abundant conformational pose for
each of the top four ZINC candidates are shown in Fig. 8A–L. The 2d ligand–protein interactions diagram for
the most abundant conformational pose of ZINC097971592, or estriol 3 glucuronide, in complex with RdRp is
shown in Fig. 8C. There were several residue contacts conserved from the ATP and RTP pose. Positive residues
R624, R555, and R553 formed H-bonds with mainly the polar negative carboxylate portion of the molecule,
indicating that this compound is situated with the polar end in the positive catalytic region of RdRp. Additionally,
ZINC097971592 also came into H-Bond contact with S682 on the hydroxyl groups on the aromatic portion. The
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Figure 5.  Average ligand RMSD values of all tested systems over the last 100 ns of simulation time (A). Average
ligand RMSF of SARS-CoV-2 RdRp for all tested systems (B).

ligand–protein contacts summary diagrams for these four ZINC candidates are displayed in Table S7 along with
the total simulation protein–ligand contact heatmap to supplement in Table S11. In this, several of the residues
seen in contact with the most abundant pose were also maintained with large occupancy through the simulation.
Residues R555 and R624 established interactions with ZINC097971592 with 89% and 74% occupancy, respectively. Interestingly, K798 formed a salt-bridge with the negative oxygen with a relatively high occupancy value
of 85%. Contacts with lesser occupancy were S682 with a 44% occupancy and R551, R553 of 50% or less. This
compound’s enantiomers were identified in a previous VirtualFlow in that there was activity towards Papain-like
protease (plpro), nucleoprotein, nsp10, nsp14 and orf7a in addition to n
 sp1276.
In Fig. 8F, the psoralen derivative ZINC002146610 also shows some similarity with the RTP pose and with
the other ZINC hits in that the polar carboxylate group is facing inwards towards the positive amino acid region
where triphosphate tail usually lays. Also, this compound formed pi–pi stacking interactions on the psoralen
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Figure 6.  The 2D structures of RTP, ATP and the top four selected ZINC compounds.
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Figure 7.  RMSF values of the template-primer RNA O5′ atoms of the ATP, RTP and four ZINC compound
systems (A) and a guide displaying nucleotide indexing values respective to the nucleotide positions on the RNA
chain (B).

ring with nucleotide U20 on the primer strand and A11 of the template strand of RNA. Additionally, the polar
end formed salt bridge and H-Bond interactions with R555 and the nearby M
 g+ ion. The ligand–protein contacts summary for ZINC002146610 shows similar contacts seen in the most abundant pose. Positive amino acid
R555 maintained an occupancy of 113% with the polar region of the molecule, meaning there were additional
contacts seen with residue in addition to the full simulation time. Like the most abundant pose, the magnesium
ion maintained full contact with the polar end via salt-bridge interactions which was seen to be further stabilized
by D618. Additional stabilizing water-bridges were established with occupancies of 47% and 48% with D623 and
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Ligand

ΔGVDW

ΔGELE

ATP

− 14.4 ± 5.0

− 15.3 ± 4.4

ΔGHYD
− 6.2 ± 0.7

ΔGTotal (kcal/mol)

Receptor RMSD (Å)

Ligand RMSD (Å)

− 35.9 ± 3.1

2.4

4.5

RTP

− 19.1 ± 4.1

6.9 ± 6.2

− 9.1 ± 1.4

− 21.3 ± 5.9

1.9

0.9

ZINC097971592

− 27.2 ± 4.4

15.2 ± 7.1

− 15.3 ± 1.7

− 37.4 ± 8.1

3.6

3.0

ZINC002146610

− 28.1 ± 3.0

12.9 ± 3.0

− 17.2 ± 1.3

− 32.4 ± 5.1

3.2

1.2

ZINC069492350

− 41.8 ± 3.1

14.3 ± 3.7

− 16.4 ± 2.1

− 43.8 ± 4.1

4.6

3.7

ZINC408592119

− 30.8 ± 3.2

23.1 ± 5.3

− 23.7 ± 1.6

− 31.4 ± 4.9

4.3

3.5

Table 3.  MM-GBSA energy values and the average receptor/ligand RMSD from the last 50 ns of 1000 ns
simulation time. VDW energies was calculated with the summation of ligand ΔGvdW energies, pi–pi
packing correction energies and the self-contact correction energies. Electrophilic terms are calculated by
the summation of coulombic, hydrogen-bonding and generalized born electrostatic solvation energies.
Hydrophilic term comprised of lipophilic energies. Total MM-GBSA (ΔGTotal) calculated in kcal/mol is
summation of ΔGvdW, ΔGele and ΔGhyd terms.

R555, respectively. Interestingly, this compound as well as its derivatives have seen previous attention in being
low toxicity potential selective and reversable inhibitors of (B5i) or the chymotrypsin-like subunit of human
immunoproteasome which is associated with the treatment of autoimmune diseases and various types of cancer77.
In Fig. 8I, conserved residue R555 is seen in contact with the polar end of ZINC69492350 in similar fashion
to the previous ZINC compounds in addition to the RTP system. Amino acid R555 has been seen to be crucial
in the activity of small molecule binding to RdRp in this study as well as others7–11,31,39–41,73,78,79. In this binding
pose of ZINC69492350, R555 forms a salt bridge to the negatively charged oxygen on the carboxyl group, with
an additional hydrogen bond contact with the partially negative doubly bonded oxygen on the carboxyl end.
Likewise, the aromatic portion of the molecule faces in direction with the hydrogen pairing nucleotide U10 on the
template strand RNA. Surrounding amino acids are also conserved which includes D760, D623, S682 and K545.
Lastly, the magnesium ions are seen to stabilize ZINC69492350 with pi-cation interactions with the thiophene
portion. In the ligand–protein contacts summary diagram in the supporting information, R555 maintained full
occupancy with the addition of other interactions less seen with a value of 150% with the polar carboxyl end of
the molecule. Like the other selected ZINC compounds, D623 formed stabilizing water-bridge interactions with
the same polar end with a value of 33%. Polar residue T687 contacted ZINC69492350 55% of the simulation,
unlike the other compounds where it served as a spectator.
In Fig. 8L, ZINC408592119 lies in a similar binding pose to ATP and RTP. According to the amino acid
contacts seen in the most abundant conformational pose of the simulation. Positive residues K551, K545, K621
and R555 were all seen to form hydrogen bonds and pi-cation interactions with partially positive groups on the
polar ends of the molecule. Negative residues such as D618 and D760 are seen to form hydrogen bonding with
partially positive portions such as on the imidizolidine group. The significance of D618 is consistent with previous studies39–41,73,78,79. In the ligand–protein contacts summary diagram in the supporting information, positive
residue K551 maintained an occupancy of 34% in the same fashion as the most abundant pose. Magnesium also
contributed full occupancy with the polar carboxyl end of the molecule consistent in Table S7 and other ZINC
candidates. Lastly, in addition to forming hydrogen bonds with the imidazolidine portion, also formed a waterbridge 76% of the simulation. Table 4 is the receptor-ligand contacts with an occurrence of greater than 30%
tabulated for the ATP, RTP and four ZINC hit complexes. Clearly, positive residues K621, R555, R553 and K551
all induced contact with more than two-thirds of the ligands selected, with R555 meeting all 5 ligands. Likewise,
negative residues D623, D798 and D760 saw interaction with at least half of the ligands. Lastly, hydrophobic
residue N691 interacted with all the selected ligands apart from ZINC408592119.
The top 5 normal modes were obtained for the four top zinc compound systems (ZINC000002146610/
Fig. S6c, ZINC000069492350/Fig. S6d, ZINC000097971592/Fig. S6e, and ZINC000408592119/Fig. S6f). The
visual inspection suggest that although these modes of the four compounds also undergo an opening to closing
motion, the magnitude is small which is more similar to RTP than ATP. Figure 9 show the mode 1 from each
system. Figure S7 show the mode that is most similar to the mode 5 of the ATP system. It can be noted that the
ZINC000408592119 undergoes similar opening to closing motions in comparison to the ATP system. It was
also observed that ZINC000002146610, ZINC000069492350, and ZINC000097971592 have similar opening and
closing motions in comparison to the RTP system.
The absorption, distribution, metabolism and excretion (ADME) properties were also explored for these
four compounds in addition to ATP and prodrug RTP using the SwissADME webserver75 (Table 5). Within the
four non-nucleoside analogs, three of them were reported to have high predicted GI absorption and cytochrome
P450 inhibition for CYP1A2, CYP2C19, CYP2C9 and CYP3A4. With these compounds being very early drug
hits selected using in silico methods, obviously there is the need for experimental evaluation needed to evaluate
their biological attributes. Additionally, it is still unclear how these compounds would behave and be metabolized
when introduced to a biological system. Based on the predicted bioavailability, three of the four compounds
possess high (56%) availability in rats.
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Figure 8.  Ligand–receptor interaction diagrams and representations of the most abundant conformational
pose from MD simulation. (A,D,G,J) The 3D cartoon representation of SARS-CoV-2 RdRp colored in gray.
(B,E,H,K) Zoomed and rotated perspective of the template-primer RNA in complex with four ZINC candidates.
(C,F,I,L) Detailed receptor-RNA-ligand contacts of the most abundant conformational pose of four ZINC
candidates. Template and primer strands represented in blue and red licorice, respectively. Ligands are colored
in green and magnesium ions are represented as pink balls.
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Residue

ATP

RTP

ZINC002146610

ZINC069492350

ZINC097971592

Y456

−

−

−

−

+

ZINC408592119
−

K545

+

−

−

+

−

−

A547

+

−

−

−

−

−

S549

+

−

−

−

+

−

A550

−

−

−

−

+

+

K551

+

+

−

−

+

+

R553

−

+

+

+

+

+

R555

+

+

+

+

+

+

T556

−

−

−

−

+

−

V557

−

−

+

+

−

−

A558

−

−

−

−

+

−

D618

−

−

+

−

−

+

Y619

−

−

+

−

−

+

K621

+

+

+

−

−

+

D623

−

+

+

+

−

+

R624

−

−

+

−

+

−

C662

−

−

+

−

−

−

S682

−

−

−

−

+

+

T687

−

−

−

+

+

−

A688

−

−

+

−

−

+

N691

+

+

+

+

+

−

D760

−

+

+

−

−

+

D761

+

−

−

−

−

−

K798

+

+

−

−

+

+

E811

+

−

−

−

−

−

R836

+

−

−

−

−

−

Table 4.  Ligand–protein contacts during simulation from ATP, RTP and the four ZINC compound systems.
Ligand–protein contacts may consist of hydrogen bonding, lipophilic, hydrophobic and electrostatic
interactions. Contacts shown are present in at least 30% of trajectory time. Bold are residues that interacted
with at least 3 of the six tested ligands.

Conclusion

In this study, we aimed to determine the binding of the active-form of remdesivir to SARS-CoV-2 RdRp in
complex with template-primer RNA and magnesium ions. Using the model constructed from PDB 7 BV244, we
then constructed a complex with ATP for further validation. We confirmed that these models were stable during the 1.0 µs MD simulation by observing the receptor/ligand RMSD and RMSF values. We then performed
HTVS of 1179 compounds from the ZINC database against the most abundant conformation obtained from
the RTP system. Based on their best docking score and low #stars, we selected the best 14 compounds form this
list. We then subjected these 14 to an additional 200 ns relaxation MD simulation as well as MM-GBSA binding
energy calculations to further elucidate more about their binding behavior and comparability to the classical
nucleotides ATP and RTP. From these results, we ultimately selected the four ZINC candidates: ZINC097971592,
ZINC002146610, ZINC69492350 and ZINC408592119 based on their lower MM-GBSA binding energy values
than that of ATP and RTP. We also observed the detailed ligand-receptor contacts for each ZINC compounds
pre and post simulation to compare their similarity in conformational pose to ATP and RTP. It was observed
that R551, R553 and R555 have significant importance relating to negative motif hydrogen bond stabilization of
both nucleotide phosphate tails and the ZINC polar ends. Additionally, negative amino acids D618 and D760
were seen to establish metal coordination bridges with Mg+ ions to further stabilization, as well as other water
bridges and hydrogen bonding interactions with nearly full occupancies. These discoveries suggest that the four
selected ligands from HTVS of the ZINC database could display similar or better binding affinity and inhibition
activities of towards RdRp in-vitro compared to traditional nucleoside analogues.
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Figure 9.  The top view (left) and the side view (right) of a selected normal mode from the top 4 ZINC systems
that is most similar to the mode 1 of RTP system. RNA (yellow) and, Thumb domain (Red), Palm domain
(Green), Finger domain (Blue) of RdRp is shown ribbon.
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Molecule

SILICOS-IT
class

GI adsorption

CYP1A2
inhibitor

CYP2C19
inhibitor

CYP2C9
inhibitor

CYP2D6
inhibitor

CYP3A4
inhibitor

Bioavalability
score

PAINS alerts

ATP

Soluble

Low

No

No

No

No

No

0.11

0

RDV

Slightly soluble

Low

No

No

No

No

Yes

0.17

0

ZINC097971592 Poorly soluble

High

Yes

No

Yes

No

No

0.56

0

ZINC002146610 Soluble

High

No

No

No

No

No

0.56

0

ZINC069492350 Soluble

Low

No

No

No

No

No

0.11

0

ZINC408592119 Poorly soluble

High

No

Yes

Yes

No

Yes

0.56

0

Table 5.  Summary of drug property predictions of ATP, RTP and top four ZINC candidates obtained from the
SwissADME webserver.
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